Skip to main content
. 2022 Mar 28;9:827524. doi: 10.3389/fcvm.2022.827524

Table 3.

Multivariable regression analysis of CA-AKI in different definition.

Variables CA-AKI 0350 CA-AKI 0525
OR (95% CI) P-Value OR (95% CI) P-Value
Dilated vs. normala 1.31 (1.06–1.61) 0.010 1.32 (1.04–1.67) 0.020
Age 1.01 (1.01–1.01) <0.001 1.02 (1.01–1.03) <0.001
Gender 1.58 (1.33–1.88) <0.001 1.23 (1.00–1.51) 0.052
AMI 1.11 (0.94–1.32) 0.205 0.81 (0.65–1.01) 0.069
HT 1.01 (0.85–1.19) 0.938 1.02 (0.83–1.25) 0.869
DM 1.11 (0.94–1.32) 0.205 1.21 (0.99–1.46) 0.056
Anemia 1.36 (1.15–1.60) <0.001 1.46 (1.21–1.77) <0.001
HFrEF 1.53 (1.21–1.94) <0.001 1.48 (1.19–1.83) <0.001
CKD 2.40 (1.99–2.90) <0.001 0.99 (0.84–1.17) 0.926
CMV>200 1.22 (0.99–1.50) 0.063 1.43 (1.13–1.81) 0.003
Diuretics 1.96 (1.65–2.34) <0.001 1.84 (1.50–2.25) <0.001

a: Dilated LVEDD compared with Normal LVEDD1.

CA-AKI0350: an absolute Scr increase ≥ 0.3 mg/dL or a relative increase in serum creatinine ≥ 50% within 48 h after contrast medium exposure.

CA-AKI0525: an absolute Scr increase ≥ 0.5 mg/dL or a relative increase in serum creatinine ≥ 25% within 72 h after contrast medium exposure.

LVEDD, left ventricular end-diastolic diameter; AMI, acute myocardial infarction; HT, hypertension; DM, diabetes mellitus; HFrEF, Heart failure with reduced ejection fraction; CKD, chronic kidney disease; CMV, contrast medium volume.